𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

✍ Scribed by Russell Scott; Mark Donoghoe; Gerald F Watts; Richard O’Brien; Christopher Pardy; Marja-Riitta Taskinen; Timothy ME Davis; Peter G Colman; Patrick Manning; Gregory Fulcher; Anthony C Keech; The FIELD Study Investigators

Book ID
115020204
Publisher
BioMed Central
Year
2011
Tongue
English
Weight
177 KB
Volume
10
Category
Article
ISSN
1475-2840

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trial finds low dose ramipril does not r
Trial finds low dose ramipril does not reduce cardiovascular or renal events in people with type 2 diabetes and albuminuria: Abstracted from: Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328(7438): 495–500.
📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 125 KB
The role of niacin in raising high-densi
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial
📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 130 KB